Retatrutide, a new dual agonist of the GLP-1 binding site and glucose-dependent insulinotropic polypeptide (GIP) target, is demonstrating promising outcomes in early human trials . Current research https://shopretatrutidepeptide.com/retatrutide-research-knowledge-hub/